Trial Profile
An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects with detrusor hyper-reflexia secondary to spinal injuries above T12.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs PSD 506 (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Plethora Solutions
- 06 May 2011 New trial record